Novo Nordisk A/S

Novo Nordisk develops and manufactures medicines for diabetes, obesity and rare diseases, earning most of its economics from patented treatments such as Ozempic and Wegovy while spending heavily on trials and manufacturing capacity to defend that franchise.

Ticker

NVO

Company

Novo Nordisk A/S

Exchange

NYSE ADR / Nasdaq Copenhagen B share

Listing

listed

Sector

Diabetes / Obesity Pharma

The bull case is that Novo Nordisk can turn the Wegovy injection, pill and higher-dose portfolio into durable global volume growth while expanding manufacturing and advancing the next obesity pipeline. The countercase is that US pricing pressure, Eli Lilly competition, semaglutide concentration, patent losses, safety or supply problems and clinical failures can reduce both growth and the value of the pipeline, while 2026 reported numbers are distorted in both directions by non-cash provision reversals, flattering Q1 and depressing the Q2 comparison.S2S4S5S6S9

• SEC identifies Novo Nordisk A/S under ticker NVO on the New York Stock Exchange. Novo Nordisk's listed Copenhagen B share trades as NOVO-B; the portfolio holds that B share rather than a separate US operating company.S1S2S5
• Each NVO American Depositary Share currently represents one deposited Novo Nordisk B share. The depositary is JPMorgan Chase Bank, and the ADS ratio can be amended under the deposit agreement.S3
• The Novo Nordisk Foundation, through Novo Holdings, owned 28.1% of the shares but controlled 77.3% of the votes at year-end 2025.S7
• Novo Nordisk's core commercial business is concentrated in Obesity and Diabetes care, led by semaglutide products including Ozempic, Wegovy and Rybelsus, with a smaller Rare Disease segment.S2S4
• Q2 2026 reported sales were DKK78.488 billion, up 2% in Danish kroner and 3% at constant exchange rates. Adjusted sales were the same DKK78.488 billion but grew 6% and 7%, because the adjustment now falls in the comparison quarter rather than the reported one.S12
• The 340B provision reversal that inflated Q1 2026 reverses the arithmetic in Q2. There was no reversal in Q2 2026, but Q2 2025 contained a DKK2.6 billion reversal, so reported Q2 growth is depressed by the prior-year base while adjusted growth is not. First-half reported sales of DKK175.311 billion still contain the DKK26.8 billion Q1 reversal, against adjusted first-half sales of DKK148.551 billion.S12
• Q2 reported operating profit was DKK27.061 billion, down 19% in Danish kroner and 16% at constant exchange rates, while adjusted operating profit was DKK33.389 billion, up 8% and 11%. The gap has two causes, the prior-year 340B base and DKK6.3 billion of non-cash impairments on intangible pipeline assets booked in Q2 2026, of which DKK4.0 billion relates to monlunabant.S12
• Q2 reported net profit was DKK20.989 billion, down 21%, and diluted earnings per share were DKK4.75, down 20%. First-half net profit was DKK69.546 billion, up 25%, a divergence that comes almost entirely from the Q1 reversal.S12
• First-half free cash flow was DKK55.3 billion against DKK38.4 billion a year earlier. Novo Nordisk attributes the increase to expense phasing, the timing of US rebate and tax payments and lower capital expenditure, none of which are durable operating improvements. The company changed its free-cash-flow definition effective Q1 2026 to net operating cash flow less purchases of property, plant and equipment.S12
• Q2 obesity-care sales rose 4% at constant exchange rates in the US and 37% internationally. Q2 GLP-1 diabetes sales rose 3% in the US on rebate adjustments, but fell 7% for the first half on lower realised prices and volumes.S12
• US Wegovy injectable sales fell 22% at constant exchange rates in Q2 on lower realised prices, partly countered by higher volumes, while US Wegovy pill sales were DKK3.141 billion. Combined Wegovy product sales in the US rose 4%. The pill is not adding to the franchise so much as holding it flat while the injectable's price erodes.S12
• Q2 Ozempic sales rose 2% at constant exchange rates, which Novo Nordisk attributes to positive rebate adjustments partly offset by lower realised prices and lower volumes. For the first half Ozempic sales fell 6%. A quarterly rebate adjustment is the same class of effect as the 340B reversal, so the Q2 improvement should not be read as recovered demand.S12
• US Operations sales rose 4% at constant exchange rates in Q2, also helped by rebate adjustments, while International Operations sales rose 10%, led by Region EUCAN at 17% and Region China at 13%. International obesity-care sales rose 37% against 4% in the US.S12
• Novo Nordisk returned DKK41.2 billion to shareholders in the first half, including DKK5.9 billion of share repurchases. By August 3 the company had repurchased 27,064,179 B shares for DKK7.533 billion under a programme of up to DKK15 billion running to February 2027. Total equity was DKK221.277 billion at the end of June, or 37.2% of total assets.S12
• Novo Nordisk raised the 2026 outlook with the Q2 report. Adjusted sales growth and adjusted operating-profit growth are now both guided at 0% to negative 6% at constant exchange rates, against negative 4% to negative 12% previously. Free-cash-flow guidance rose to DKK45 to 55 billion. Both measures exclude the 340B reversal and are forecasts.S12
• The company states that on a non-adjusted basis the mid-point of its 2026 guidance would be 5% sales growth and 12% operating-profit growth at constant exchange rates. The same year therefore reads as a mild decline or as solid growth depending purely on which base is used, which is why the adjusted and reported figures always belong side by side.S12
• Fiscal 2025 sales were DKK309.064 billion, up 6% in Danish kroner and 10% at constant exchange rates.S2S6
• Fiscal 2025 operating profit was DKK127.658 billion, down 1% in Danish kroner but up 6% at constant exchange rates. The year included around DKK8 billion of company-wide restructuring costs.S2S6
• Fiscal 2025 net profit was DKK102.434 billion and diluted earnings per share were DKK23.03.S2S6
• Fiscal 2025 free cash flow was DKK28.295 billion, while property, plant and equipment capital expenditure was DKK60.1 billion as Novo Nordisk expanded production capacity.S2S6
• Fiscal 2025 research and development expense was DKK52.039 billion, equal to 16.8% of sales.S2S6
• The 2026 share-repurchase authorisation is up to DKK15 billion. Through July 24, Novo Nordisk reported repurchasing 25.919 million B shares for DKK7.162 billion; it held 43.104 million treasury B shares, equal to about 1.0% of share capital.S10
• The ZEUS phase 3 trial of ziltivekimab did not reduce major adverse cardiovascular events versus placebo, with a hazard ratio of 0.99 and a 95% confidence interval of 0.88 to 1.11. Novo Nordisk expects a non-cash Q3 impairment but said the result does not change its previously communicated 2026 adjusted operating-profit outlook.S9
• Novo Nordisk terminated the monlunabant development project and wrote down DKK4.0 billion of the related intangible asset in Q2 2026, part of DKK6.3 billion of pipeline impairments in the quarter. This is separate from the ZEUS ziltivekimab failure, whose impairment the company has guided to Q3.S12S9

• narrativeEarnings-quality interpretation: reported Q1 growth mostly describes an accounting release of a non-cash 340B provision, and reported Q2 weakness mostly describes the same effect sitting in the prior-year base. Adjusted Q2 operating profit growth of 11% is the cleaner signal, but it excludes a real DKK6.3 billion pipeline write-down.
• narrativeFranchise interpretation: Wegovy pill and higher-dose Wegovy can expand the addressable market, but launch prescriptions, wholesaler pipeline fill and self-pay uptake do not automatically prove durable net revenue after rebates.
• narrativePipeline interpretation: obesity assets create multiple shots on goal, but ZEUS is a live reminder that biological activity and a large phase 3 trial do not guarantee a commercially useful endpoint.
• narrativeOwnership interpretation: foundation control can support long-term investment, but public B-share and ADR holders cannot outvote Novo Holdings on ordinary governance matters.

• ▸US realised prices, rebates and gross-to-net deductions can fall faster than prescription volumes rise. Q1 adjusted US sales fell 11% at constant exchange rates despite Wegovy volume growth, and Q2 US Wegovy injectable sales fell 22% on price while volumes rose.S2S4
• ▸Competition from other approved and investigational obesity and diabetes medicines can reduce market share, pricing power and formulary access.S2
• ▸The DKK26.8 billion 340B reversal shows that legal interpretations and rebate estimates can materially move reported sales and profit without moving cash.S2S4
• ▸Novo Nordisk is heavily concentrated in semaglutide and GLP-1 products. Safety issues, demand changes or patent losses affecting that molecule can hit several brands at once.S2
• ▸Patents and regulatory exclusivity expire at different times across countries. Biosimilar or generic competition can reduce prices and volumes after loss of exclusivity.S2S6
• ▸Clinical programmes can miss primary endpoints or produce weaker-than-expected benefit. ZEUS failed to reduce cardiovascular events and will trigger a Q3 impairment.S9
• ▸Investigational drugs can fail in development or at regulators. Pipeline value should not be counted as approved revenue.S2S9
• ▸GLP-1 and insulin products carry labelled safety, dosing and tolerability risks. Adverse events or medication errors can affect patients, labels and demand.S2S11
• ▸Manufacturing expansion is expensive and technically complex. Quality failures, shortages, delayed capacity or underused plants can damage sales and returns on capital.S2S6
• ▸Wholesaler pipeline fill can pull revenue into a launch quarter. Wegovy pill's Q1 sales therefore should not be annualised mechanically.S4S5
• ▸Prescription counts are not patient counts or net sales. Capture gaps across channels, dose changes, discontinuation and rebates can break a simple prescriptions-times-price model.S4
• ▸Currency moves change reported Danish-krone sales and profit. Constant-exchange-rate growth is a management comparison, not the cash currency result.S2S4
• ▸Novo Holdings controls a majority of votes with a minority economic stake. Public B-share and ADR holders have limited influence over governance outcomes.S2S7
• ▸Heavy capital expenditure, acquisitions and licensed assets can consume cash and create impairment risk if demand or clinical outcomes disappoint.S2S6S9
• ▸Buy-backs and dividends depend on cash generation and board decisions. An authorised DKK15 billion programme is not the same as completed cancellation of all authorised shares.S4S10
• ▸Reported and adjusted figures diverge in both directions across 2026, and the direction flipped between Q1 and Q2. Any single-quarter growth rate quoted without stating which basis it uses will mislead, and that applies to the company's own headline as much as to third-party summaries.S12

ADR

— A US-traded receipt representing shares deposited with a bank. One NVO ADS currently represents one Novo Nordisk B share.

B share

— Novo Nordisk's publicly listed share class on Nasdaq Copenhagen. It has less voting power per share than the unlisted A class.

A share

— Novo Nordisk's unlisted high-vote share class held through Novo Holdings and ultimately the Novo Nordisk Foundation.

CER

— Constant exchange rates, a comparison that removes currency translation effects to show underlying commercial movement.

Reported sales

— IFRS sales in the accounts, including the Q1 340B provision reversal.

Adjusted sales

— Novo Nordisk's non-IFRS sales measure excluding the exceptional Q1 340B provision reversal.

340B

— A US drug-pricing programme requiring discounts for eligible covered entities. Novo Nordisk's accounting provision depended partly on legal interpretation.

Gross-to-net

— The gap between list-price sales and net revenue after rebates, discounts, returns and other deductions.

GLP-1

— A drug class that acts on the glucagon-like peptide-1 receptor and is used in diabetes and weight-management treatments.

Semaglutide

— The active molecule used in Novo Nordisk brands including Ozempic, Wegovy and Rybelsus.

Obesity care

— Novo Nordisk's commercial therapy area for chronic weight-management medicines such as Wegovy and Saxenda.

Operating profit

— Profit after operating costs but before financial items and tax. Q1 reported operating profit included the 340B effect.

Adjusted operating profit

— Novo Nordisk's non-IFRS operating-profit measure excluding the exceptional 340B reversal.

Free cash flow

— From 2026, Novo Nordisk defines this as operating cash flow minus purchases of property, plant and equipment.

Pipeline fill

— Initial stocking by wholesalers or partners before and around a launch, which can temporarily lift manufacturer sales.

Prescription count

— A count of filled prescriptions, not necessarily unique patients, treatment persistence or manufacturer net revenue.

Loss of exclusivity

— The point when patent or regulatory protection ends and competitors can enter with generic or biosimilar products.

Impairment

— A non-cash reduction in an asset's accounting value when expected future economics deteriorate.

Treasury shares

— Shares repurchased and held by the company. They do not carry voting rights while held in treasury.

Share repurchase

— Company purchases of its own shares. Authorisation sets a ceiling; only completed purchases reduce cash and may later be cancelled.